ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0923

Criteria for the Diagnosis of Raynaud’s Phenomenon – Do They Recognize the Same Patients?

Martina Plešivčnik-Novljan1, Daša Šuput Skvarča1, Ajda Jezernik1, Saša Čučnik1, Žiga Rotar1 and Alojzija Hocevar2, 1University Medical Center Ljubljana, Ljubljana, Ljubljana, Slovenia, 2University Medical Center, Rheumatology, Ljubljana, LJUBLJANA, Slovenia

Meeting: ACR Convergence 2020

Keywords: Raynaud's

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Different criteria aiding the diagnosis of Raynaud’s phenomenon (RP) have been proposed. Wigley’s “RP criteria 2002”, defined RP by history of cold sensitivity, accompanied by pallor and/or cyanosis, and a 3-item questionnaire1. International Consensus Criteria proposed criteria (“RP criteria 2014”) take a three-step conditional approach (i.e. a screening question, assessment of colour changes and a disease score calculation2. As the latter criteria seem more stringent for RP, we aimed to compare the agreement between the two criteria sets and their correlation with nailfold capillaroscopy (NFC) findings and results of immunoserological tests.

Methods: This cross-sectional study was performed between January 2018 and December 2019 at our secondary/tertiary rheumatology centre. Both RP criteria questionnaires were applied by the rheumatologist to all patients and the same day the NFC was done. The agreement between the criteria was determined by the Cohen κ-test. The correlation between the two criteria sets, NFC and immunoserological tests (antinuclear antibodies and scleroderma specific antibodies) was calculated with the Pearson correlation test.

Results: We included 565 consecutive patients referred for NFC (84.1% female, median age (IQR) 51.1 (40.1–61.6) years). “RP criteria 2002” and “RP criteria 2014” were fulfilled in 485/565 (85.8%) and 248/565 (43.9%) patients, respectively. The κ-coefficient of agreement between the criteria was 0.22 (95% CI 0.11-0.26). Table 1 shows the correlations between RP criteria and results of NFC and immunoserology.

Conclusion: We found a low level of agreement between the two criteria sets. “RP criteria 2014” correlated better than “RP criteria 2002” with scleroderma specific immunoserology and the scleroderma pattern at NFC, albeit the correlation was low for both criteria.

Legend: * Pearson correlation coefficient (95%CI) and p value; ANA antinuclear antibody; Ab antibody; ENA extractable nuclear antigen; $ ACmA or anti-Scl70; # any type of pathological result; NFC nailfold capillaroscopy;


Disclosure: M. Plešivčnik-Novljan, None; D. Šuput Skvarča, None; A. Jezernik, None; S. Čučnik, None; �. Rotar, None; A. Hocevar, None.

To cite this abstract in AMA style:

Plešivčnik-Novljan M, Šuput Skvarča D, Jezernik A, Čučnik S, Rotar �, Hocevar A. Criteria for the Diagnosis of Raynaud’s Phenomenon – Do They Recognize the Same Patients? [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/criteria-for-the-diagnosis-of-raynauds-phenomenon-do-they-recognize-the-same-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/criteria-for-the-diagnosis-of-raynauds-phenomenon-do-they-recognize-the-same-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology